In the case of KRAS G12C inhibitor therapy, SHP2 inhibition in combination with KRAS G12C inhibition, using SHP099 and ARS-1620, respectively, was shown to confer alterations to the tumour microenvironment and a decrease in MAPK pathway activation, thereby inhibiting tumour growth (Fedele et al., 2020). Here, KRAS is linked to neoplasm.